Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05261750
PHASE1/PHASE2

Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Sponsor: PT. Prodia Stem Cell Indonesia

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.

Official title: Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2022-04-30

Completion Date

2026-02-28

Last Updated

2026-02-25

Healthy Volunteers

No

Interventions

OTHER

Placebo (Aqua Pro-Injection)

Treatment with Aqua Pro-Injection 2 cc 2 times injection, interval 2 days (via Intramuscular).

BIOLOGICAL

Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy)

Treatment with Aqua Pro-Injection 2 cc, and then followed by Auto DC, interval 2 days (via Intramuscular)

BIOLOGICAL

Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)

Treatment with Allo-DC-Secretome 2 cc, and then followed by Auto DC, interval 2 days (via Intramuscular)

Locations (1)

PT Prodia StemCell Indonesia

Jakarta, Indonesia